BioLegend社ウェビナーが開催されます。ご登録者には後日オンデマンド配信がございますので、日本時間深夜帯ですがご登録お待ちしております。
Acute myeloid leukemia (AML) is a hematopoietic malignancy with poor prognosis and limited treatment options. Here we provide a comprehensive census of the bone marrow immune microenvironment in adult and pediatric AML patients. We characterize unique inflammation signatures in a subset of AML patients associated with inferior outcomes. We identify atypical B cells, a dysfunctional B cell subtype enriched in high-inflammation AML patients, as well as an increase in CD8+ GZMK+ and regulatory T cells. This is accompanied by a reduction in T cell clonal expansion. We derive an inflammation-associated gene score (iScore) that associates with poor survival outcomes in AML patients. Addition of the iScore refines current risk stratifications for AML patients and may enable identification of patients in need of more aggressive treatment. This work provides a framework for classifying AML patients based on their immune microenvironment and a rationale for consideration of the inflammatory state in clinical settings.
What you will learn:
– Use of CITE-Seq antibodies to characterize the immune microenvironment in AML
– Use of CITE-Seq to characterize inflammatory responses in AML
– Integration of CITE-Seq with bulk RNA-Seq data to derive prognostic gene signatures
Speaker:
Audrey Lasry, PhD Department of Pathology, NYU Langone.
Audrey completed her PhD in the Hebrew University in Jerusalem, and is now a postdoctoral fellow in the lab of Dr. Iannis Aifantis at NYU Langone. Her research focuses on the role of the immune microenvironment in leukemia.